EFFICACY OF VILPRAFEN AND RESISTOL IN COMMUNITY-ACQUIRED PNEUMONIA WITH ATYPICAL ETIOLOGY IN CHILDREN
Keywords:
treatment, atypical pneumonia, children, vilprafen, resistolAbstract
Improving treatment tactics for pneumonia is one of the most urgent problems of modern pediatrics. We conducted a survey of 120 patients with community-acquired pneumonia aged 6 months to 14 years, divided into 2 groups: Group I - 60 patients with mycoplasmal and chlamydial etiology who received standard therapy, Group II - 60 patients who received vilprafen and resistol in the complex of standard therapy. Vilprafen was administered at 50 mg/kg in 2-3 doses per day orally, Resistol for children from 1 year to 6 years 10 drops 3 times a day, from 6 to 12 years 20 drops 3 times a day. The drugs were used throughout the course of treatment.
References
Diagnostic algorithms and protocols for providing medical care for pneumonia: guidelines for doctors / Demko I.V., Chubarova S.V., Gordeeva N.V., Zeleny S.V. and etc.; Ministry of Health of the Krasnoyarsk Territory, Krasnoyarsk State Medical University. prof. V.F. Voyno-Yasenetsky Ministry of Health of Russia. M., 2015. 75 p.
Gorbich, O. A. (2016). SARS is a significant problem in childhood. Medical Journal, 3, 57-61.
Ibragimova M., Shavazi, N., Lim, M., & Atayeva, M. (2022). Diagnostic and therapeutic methods for community-acquired pneumonia with atypical etiology in children. Journal of Physician's Bulletin, 1(4 (101), 30–33. https://doi.org/10.38095/2181-466X-20211014-29-32
Sinopalnikov A.I., Andreeva I.V., Stetsyuk O.U. Safety of macrolide antibiotics: a critical analysis. Clinical medicine. 2012.3:23-30.
Trubnikov, G. V., Polyakova, I. G., Butakova, L. Yu. (2010). Pneumonia at the prehospital stage: clinical features, taking into account atypical (mycoplasmal and chlamydial) infections in etiology according to retrospective diagnostics. New St. Petersburg Medical Gazette, 1 (51), 59–63.
Fedorovna, ibragimova marina. "The influence of risk factors on the development of atypical pneumonia in young children." Asian journal of pharmaceutical and biological research 11.2 (2022).
Shavazi, N., Ibragimova M., Atayeva, M., Zakirova, B., & Lim, M. (2022). Improving the treatment of pneumoniae with atypical etiology in children. Doktor Axborotnomasi Jurnali,1(2 (99), 109–112. https://doi.org/10.38095/2181-466X-2021992-108-111
Elphick H, AS Rigby, Everard ML. Phenotype Of Acute Respiratory Syncytial Virus Lower Respiratory Tract Illness in Infancy And Subsequent Morbidity // Acta Pediatrica. №. 96. 2007. p. 1-3.
